All the hurdles in developing drugs to fight cancer in children came to the fore this week as the Pediatric Oncology Subcommittee of the FDA’s Oncology Drugs Advisory Committee (ODAC) grappled with the unknowns of science and a pressing unmet need as they discussed global pediatric development plans for Bristol-Myers Squibb Co.’s (BMS) nivolumab, Merck Sharp and Dohme’s MK-3475 and Novartis Pharmaceuticals Corp.’s LEE011.